Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Lebanon, NH
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lebanon, NH
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Albuquerque, NM
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albuquerque, NM
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Medford, OR
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Medford, OR
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Providence, RI
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Providence, RI
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection
Status: Archived
Local Institution
mi
from
Inglewood, CA
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection
Status: Archived
Updated: 1/1/1970
Local Institution
mi
from
Inglewood, CA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir
A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir
A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
Holy Cross Hospital of Silver Spring
mi
from
Silver Spring, MD
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
Holy Cross Hospital of Silver Spring
mi
from
Silver Spring, MD
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
Occupational Medicine Services
mi
from
Annandale, VA
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
Occupational Medicine Services
mi
from
Annandale, VA
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
Inova Fairfax Hospital
mi
from
Falls Church, VA
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
Inova Fairfax Hospital
mi
from
Falls Church, VA
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
MedStar Washington Hospital Center
mi
from
Washington,
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated:  12/31/1969
University of Arkansas
mi
from
Little Rock, AR
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated: 12/31/1969
University of Arkansas
mi
from
Little Rock, AR
Click here to add this to my saved trials
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated:  12/31/1969
University of Tennessee
mi
from
Memphis, TN
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated: 12/31/1969
University of Tennessee
mi
from
Memphis, TN
Click here to add this to my saved trials
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Baylor University
mi
from
Dallas, TX
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Baylor University
mi
from
Dallas, TX
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Denver, CO
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Transplant Patient Registry of Liver, Kidney and/or Pancreas
Transplant Registry: Patients Who May Require Transplantation and Those Who Have Undergone Transplantation of Liver, Kidney and/or Pancreas
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Health System
mi
from
Richmond, VA
Transplant Patient Registry of Liver, Kidney and/or Pancreas
Transplant Registry: Patients Who May Require Transplantation and Those Who Have Undergone Transplantation of Liver, Kidney and/or Pancreas
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Health System
mi
from
Richmond, VA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
Veterans Administration Long Beach Medical Center
mi
from
Long Beach, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
Veterans Administration Long Beach Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
Veterans Administration Los Angeles Healthcare System
mi
from
Los Angeles, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
Veterans Administration Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Hepatitis C Treatment and Atherosclerosis
Hepatitis C Eradication and Progression of Atherosclerosis
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Hepatitis C Treatment and Atherosclerosis
Hepatitis C Eradication and Progression of Atherosclerosis
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
A Pilot Study of Therapy With Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects With Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy
Status: Enrolling
Updated:  12/31/1969
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
A Pilot Study of Therapy With Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects With Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy
Status: Enrolling
Updated: 12/31/1969
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Click here to add this to my saved trials